References

  1. 1.Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):E45-E67.
  2. 2.File TM, Ramirez JA. Community-acquired pneumonia. New Engl J Med. 2023;389(7):632-641.
  3. 3.Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471.
  4. 4.McDermott KW, Roemer M. Most frequent principal diagnoses for inpatient stays in U.S. hospitals, 2018. Healthcare cost and utilization project (HCUP) statistical briefs. https://www.ncbi.nlm.nih.gov/books/NBK573113/
  5. 5.Murphy SL, Kochanek KD, Xu J, et al. Centers for Disease Control and Prevention. Mortality in the United States, 2020 Key findings data from the National Vital Statistics system. https://www.cdc.gov/nchs/products/index.htm
  6. 6.Ramirez JA, Wiemken TL, Peyrani P, et al.; University of Louisville Pneumonia Study Group. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806-1812.
  7. 7.File TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130-141.
  8. 8.Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250.
  9. 9.Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-141.
  10. 10.Faner R, Sibila O, Agustí A, et al. The microbiome in respiratory medicine: current challenges and future perspectives. Eur Respir J. 2017;49(4):1602086.
  11. 11.Jain S, Self WH, Wunderink RG, et al.; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427.
  12. 12.Gadsby NJ, Musher DM. The microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to host transcriptional signatures. Clin Microbiol Rev. 2022;35(4):e0001522.
  13. 13.Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50(2):202-209.
  14. 14.File TM, Marrie TJ. Does empiric therapy for atypical pathogens improve outcomes for patients with CAP? Infect Dis Clin North Am. 2013;27(1):99-114.
  15. 15.Arnold FW, Summersgill JT, Lajoie AS, et al.; Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175(10):1086-1093.
  16. 16.Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis. 2011;52(suppl 4):S346-S350.
  17. 17.Centers for Disease Control and Prevention. Antibiotic-resistant Streptococcus pneumoniae. https://www.cdc.gov/pneumococcal/php/drug-resistance/index.html
  18. 18.Henig O, Kaye KS. Bacterial pneumonia in older adults. Infect Dis Clin North Am. 2017;31(4):689-713.
  19. 19.Xirouchaki N, Magkanas E, Vaporidi K, et al. Lung ultrasound in critically ill patients: comparison with bedside chest radiography. Intensive Care Med. 2011;37(9):1488-1493.
  20. 20.Díaz-Gómez JL, Mayo PH, Koenig SJ. Point-of-care ultrasonography. N Engl J Med. 2021;385(17):1593-1602.
  21. 21.Bishop BM, Bon JJ, Trienski TL, et al. Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit. Ann Pharmacother. 2014;48(5):577-583.
  22. 22.Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017(10):CD007498.
  23. 23.Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019;57(9):1308-1318.
  24. 24.Rhee C, Mansour MK. Procalcitonin use in lower respiratory tract infections. UpToDate. https://sso.uptodate.com/contents/procalcitonin-use-in-lower-respiratory-tract-infections
  25. 25.Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382.
  26. 26.File TM. New diagnostic tests for pneumonia: what is their role in clinical practice? Clin Chest Med. 2011;32(3):417-430.
  27. 27.Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA’s diagnostics committee. Clin Infect Dis. 2020;71(10):2744-2751.
  28. 28.Burillo A, Candel FJ, Canut-Blasco A. Value of syndromic panels in the management of severe community-acquired pneumonia. Rev Esp Quimioter. 2022;35(suppl 1):15-20.
  29. 29.Gentilotti E, De Nardo P, Cremonini E, et al. Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections. A systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(1):13-22.
  30. 30.Falsey AR, Branche AR, Croft DP, et al. Real-life assessment of Bio-Fire FilmArray pneumonia panel in adults hospitalized with respiratory illness. J Infect Dis. 2024;229(1):214-222.
  31. 31.Parente DM, Cunha CB, Mylonakis E, et al. The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. Clin Infect Dis. 2018;67(1):1-7.
  32. 32.Gupta V, Yu KC, Schranz J, et al. A multicenter evaluation of the US prevalence and regional variation in macrolide-resistant S. pneumoniae in ambulatory and hospitalized adult patients in the United States. Open Forum Infect Dis. 2021;8(7):ofab063.
  33. 33.File TM, Goldberg L, Das A, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clin Infect Dis. 2019;69(11):1856-1867.
  34. 34.Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517-527.
  35. 35.Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49(6):615-632.
  36. 36.Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med. 2019;380(7):651-663.
  37. 37.Infectious Diseases Society of America. IDSA Guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/COVID19guidelines
  38. 38.Saleem N, Kulkarni A, Snow TAC, et al. Effect of corticosteroids on mortality and clinical cure in community-acquired pneumonia. Chest. 2023;163(3):484-497.
  39. 39.Bergmann F, Pracher L, Sawodny R, et al. Efficacy and safety of corticosteroid therapy for community-acquired pneumonia. Clin Infect Dis. 2023;77(12):1704-1713.
  40. 40.Dequin PF, Meziani F, Quenot JP, et al.; CRICS-TriGGERSep Network. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388(21):1931-1941.
  41. 41.Lansbury L, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019(2):CD010406.
  42. 42.Parody R, Martino R, Sánchez F, et al. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation. Am J Hematol. 2009;84(9):571-578.
  43. 43.van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax. 2005;60(8):672-678.
  44. 44.Viasus D, Simonetti AF, Garcia-Vidal C, et al. Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. J Antimicrob Chemother. 2017;72(2):547-553.
  45. 45.Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155(12):1273-1276.
  46. 46.Aliberti S, Zanaboni AM, Wiemken T, et al. Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. Eur Respir J. 2013;42(3):742-749.
  47. 47.Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008;68(13):1841-1854.
  48. 48.el Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332(7554):1355.
  49. 49.Dinh A, Ropers J, Duran C, et al.; Pneumonia Short Treatment (PTC) Study Group. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021;397(10280):1195-1203.
  50. 50.Tak HJ, Chen LW, Wilson FA, et al. Post-discharge services for different diagnoses than index hospitalization predict decreased 30-day readmissions among Medicare beneficiaries. J Gen Intern Med. 2019;34(9):1766-1774.
  51. 51.Krist AH, Davidson KW, Mangione CM, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970.
  52. 52.Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med. 1999;159(9):970-980.
  53. 53.Menéndez R, Torres A, Zalacaín R, et al.; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59(11):960-965.
  54. 54.Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest. 2008;134(5):955-962.
  55. 55.Feldman C, Anderson R. Pneumonia as a systemic illness. Curr Opin Pulm Med. 2018;24(3):237-243.
  56. 56.Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47(2):182-187.
  57. 57.Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-274.
  58. 58.Rivero-Calle I, Cebey-López M, Pardo-Seco J, et al. Lifestyle and comorbid conditions as risk factors for community-acquired pneumonia in outpatient adults (NEUMO-ES-RISK project). BMJ Open Respir Res. 2019;6(1):e000359.
  59. 59.Centers for Disease Control and Prevention. Adult immunization schedule by age. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-schedule-vaccines.html
  1. 1.Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111.
  2. 2.Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J. 2017;50(3):1700582.
  3. 3.Magill SS, O’Leary E, Janelle SJ, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018;379(18):1732-1744.
  4. 4.Modi AR, Kovacs CS. Hospital-acquired and ventilator-associated pneumonia: diagnosis, management, and prevention. Cleve Clin J Med. 2020;87(10):633-639.
  5. 5.Candel FJ, Salavert M, Estella A, et al. Ten issues to update in nosocomial or hospital-acquired pneumonia: an expert review. J Clin Med. 2023;12(20):6526.
  6. 6.Motowski H, Ilges D, Hampton N, et al. Determinants of mortality for ventilated hospital-acquired pneumonia and ventilator-associated pneumonia. Crit Care Explor. 2023;5(3):e0867.
  7. 7.Luyt CE, Hékimian G, Koulenti D, et al. Microbial cause of ICU-acquired pneumonia. Curr Opin Crit Care. 2018;24(5):332-338.
  8. 8.Klompas M, Branson R, Cawcutt K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and non-ventilator hospital-acquired pneumonia in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2022;43(6):687-713.
  9. 9.Zilberberg MD, Nathanson BH, Puzniak LA, et al. Descriptive epidemiology and outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2012-2019. Crit Care Med. 2022;50(3):460-468.
  10. 10.Morrow L, Kollef M. Hospital-acquired pneumonia. In: Jong EC, Stevens DL, eds. Netter’s Infectious Diseases. 2nd ed. Elsevier; 2022.
  11. 11.Ferrer M, Torres A. Epidemiology of ICU-acquired pneumonia. Curr Opin Crit Care. 2018;24(5):325-331.
  12. 12.Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest. 1988;93(2):318-324.
  13. 13.Kim BG, Kang M, Lim J, et al. Comprehensive risk assessment for hospital-acquired pneumonia. BMC Pulm Med. 2022;22(1):21.
  14. 14.Rautaporras N, Furuholm J, Uittamo J, et al. Deep odontogenic infections-identifying risk factors for nosocomial pneumonia. Clin Oral Investig. 2021;25(4):1925-1932.
  15. 15.Huang HB, Jiang W, Wang CY, et al. Stress ulcer prophylaxis in intensive care unit patients receiving enteral nutrition. Crit Care. 2018;22(1):20.
  16. 16.Barbateskovic M, Marker S, Granholm A, et al. Stress ulcer prophylaxis with proton pump inhibitors or histamin-2 receptor antagonists in adult intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2019;45(2):143-158.
  17. 17.File TM. Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines. Clin Infect Dis. 2010;51(suppl 1):S42-S47.
  18. 18.Fàbregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited. Thorax. 1999;54(10):867-873.
  19. 19.Grossman RF, Fein A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Executive summary. Chest. 2000;117(4 suppl 2):177S-181S.
  20. 20.Fernando SM, Tran A, Cheng W, et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients—a systematic review and meta-analysis. Intensive Care Med. 2020;46(6):1170-1179.
  21. 21.Weber DJ, Rutala WA, Sickbert-Bennett EE, et al. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28(7):825-831.
  22. 22.Zilberberg MD, Nathanson BH, Puzniak LA, et al. Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014-2019. Infect Control Hosp Epidemiol. 2022;43(3):277-283.
  23. 23.Agarwal S, Abell V, File TM. Nosocomial (health care-associated) Legionnaire’s disease. Infect Dis Clin North Am. 2017;31(1):155-165.
  24. 24.Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect. 2006;63(3):246-254.
  25. 25.Zilberbeg MD, Khan I, Shorr AF. Respiratory viruses in nosocomial pneumonia: an evolving paradigm. Viruses. 2023;15(8):1676.
  26. 26.Luyt CE, Bréchot N, Chastre J. What role do viruses play in nosocomial pneumonia? Curr Opin Infect Dis. 2014;27(2):194-199.
  27. 27.Du Q, Zhang D, Hu W, et al. Nosocomial infection of COVID19. Int J Mol Med. 2021;47(4):31.
  28. 28.Centers for Disease Control and Prevention. Antimicrobial resistance threats in the United States, 2021-2022. https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html
  29. 29.Zasowski EJ, Bassetti M, Blasi F, et al. A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections. Chest. 2020;158(3):929-938.
  30. 30.Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections. Clin Infect Dis. 2020;71(10):2744-2751.
  31. 31.Stafylaki D, Maraki S, Vaporidi K, et al. Impact of molecular syndromic diagnosis of severe pneumonia in the management of critically ill patients. Microbiol Spectr. 2022;10(5):e0161622.
  32. 32.Muscedere JG, Shorr AF, Jiang X, et al. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. J Crit Care. 2012;27(3):322.e7-322.e14.
  33. 33.Kollef MH, Shorr AF, Bassetti M, et al. Timing of antibiotic therapy in the ICU. Crit Care. 2021;25(1):360.
  34. 34.Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23(1):91-100.
  35. 35.Humphries RM. Updated aminoglycoside breakpoints for Enterobacterales and Pseudomonas aeruginosa. Clinical and Laboratory Standards Institute. https://clsi.org/about/blog/ast-news-update-june-2023-new-clsi-m100-ed33-updated-aminoglycoside-breakpoints-for-enterobacterales-and-pseudomonas-aeruginosa/
  36. 36.Gamazo JJ, Candel FJ, Del Castillo JG. Nosocomial pneumonia. Rev Esp Quimioter. 2023;36(suppl 1):9-14.
  37. 37.Bassetti M, Mularoni A, Giacobbe DR, et al. New antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia. Semin Respir Crit Care Med. 2022;43(2):280-294.
  38. 38.Shen Y, Kuti JL. Optimizing antibiotic dosing regimens for nosocomial pneumonia. Expert Opin Drug Metab Toxicol. 2023;19(1):13-25.
  39. 39.Parente DM, Cunha CB, Mylonakis E, et al. The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia. Clin Infect Dis. 2018;67(1):1-7.
  40. 40.Ewig S. Nosocomial pneumonia: de-escalation is what matters. Lancet Infect Dis. 2011;11(3):155-157.
  41. 41.Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006;129(5):1210-1218.
  42. 42.Eachempati SR, Hydo LJ, Shou J, et al. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma. 2009;66(5):1343-1348.
  43. 43.Ranzani OT, Ferrer M, Esperatti M, et al. Association between systemic corticosteroids and outcomes of intensive care unit–acquired pneumonia. Crit Care Med. 2012;40(9):2552-2561.
  44. 44.Chastre J, Wolff M, Fagon JY, et al.; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588-2598.
  45. 45.Pugh R, Grant C, Cooke RPD, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015(8):CD007577.
  46. 46.Dimopoulos G, Poulakou G, Pneumatikos IA, et al. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest. 2013;144(6):1759-1767.
  47. 47.Chastre J, Luyt CE. Optimising the duration of antibiotic therapy for ventilator-associated pneumonia. Eur Respir Rev. 2007;16(103):40-44.
  48. 48.Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019;57(9):1308-1318.
  49. 49.Wang R, Zhang J, He M, et al. Procalcitonin as a biomarker of nosocomial pneumonia in aneurysmal subarachnoid hemorrhage patients treated in neuro-ICU. Clin Neurol Neurosurg. 2023;231:107870.
  50. 50.Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018;22(1):191.
  51. 51.Wunderink RG. Welkommen to our world. Emergence of antibiotic resistance with selective decontamination of the digestive tract. Am J Respir Crit Care Med. 2010;181(5):426-427.
  52. 52.Kollef MH, Micek ST. Rational use of antibiotics in the ICU: balancing stewardship and clinical outcomes. JAMA. 2014;312(14):1403-1404.
  1. 1.Di Pasquale MF, Sotgiu G, Gramegna A, et al.; GLIMP Investigators. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis. 2019;68(9):1482-1493.
  2. 2.Jain S, Self WH, Wunderink RG, et al.; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427.
  3. 3.Sousa D, Justo I, Domínguez A, et al. Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome. Clin Microbiol Infect. 2013;19(2):187-192.
  4. 4.Ramirez JA, Chandler TR, Furmanek SP, et al.; Louisville CAP in the Immunocompromised Study Group. Community-acquired pneumonia in the immunocompromised host: epidemiology and outcomes. Open Forum Infect Dis. 2023;10(11):ofad565.
  5. 5.Centers for Disease Control and Prevention. People who are immunocompromised. https://archive.cdc.gov/www_cdc_gov/coronavirus/2019-ncov/need-extra-precautions/people-who-are-immunocompromised.html
  6. 6.Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. Chest. 2020;158(5):1896-1911.
  7. 7.Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316(23):2547-2548.
  8. 8.Jenkinson PW, Plevris N, Siakavellas S, et al. Temporal trends in surgical resection rates and biologic prescribing in Crohn’s disease: a population-based cohort study. J Crohns Colitis. 2020;14(9):1241-1247.
  9. 9.Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639.
  10. 10.Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659-667.
  11. 11.United Network for Organ Sharing. OPTN Metrics. https://insights.unos.org/OPTN-metrics/
  12. 12.Gonzalez C, Johnson T, Rolston K, et al. Predicting pneumonia mortality using CURB-65, PSI, and patient characteristics in patients presenting to the emergency department of a comprehensive cancer center. Cancer Med. 2014;3(4):962-970.
  13. 13.Sanders KM, Marras TK, Chan CKN. Pneumonia severity index in the immunocompromised. Can Respir J. 2006;13(2):89-93.
  14. 14.National Institutes of Health, HIV Medicine Association, Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/pneumocystis?view=full
  15. 15.Wieruszewski PM, Barreto JN, Frazee E, et al. Early corticosteroids for pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest. 2018;154(3):636-644.
  16. 16.Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis. Clin Infect Dis. 2009;48(12):1743-1751.
  17. 17.Restrepo A, Clark NM. Nocardia infections in solid organ transplantation: guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation. Clin Transplant. 2019;33(9):e13509.
  18. 18.Mirouse A, Vignon P, Piron P, et al. Severe varicella-zoster virus pneumonia: a multicenter cohort study. Crit Care. 2017;21(1):137.
  19. 19.Travi G, Pergam SA. Cytomegalovirus pneumonia in hematopoietic stem cell recipients. J Intensive Care Med. 2014;29(4):200-212.
  20. 20.Lodding IP, Schultz HH, Jensen JU, et al. Cytomegalovirus viral load in bronchoalveolar lavage to diagnose lung transplant associated CMV pneumonia. Transplantation. 2018;102(2):326-332.
  21. 21.Machado CM, Dulley FL, Boas LS, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant. 2000;26(4):413-417.
  22. 22.Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. 2004;17(1):208-217.
  23. 23.Patrat-Delon S, Gangneux JP, Lavoué S, et al. Correlation of parasite load determined by quantitative PCR to clinical outcome in a heart transplant patient with disseminated toxoplasmosis. J Clin Microbiol. 2010;48(7):2541-2545.
  1. 1.Sperling S, Dahl VN, Fløe A. Lung abscess: an update on the current knowledge and call for future investigations. Curr Opin Pulm Med. 2024;30(3):229-234.
  2. 2.Kuhajda I, Zarogoulidis K, Tsirgogianni K, et al. Lung abscess-etiology, diagnostic and treatment options. Ann Transl Med. 2015;3(13):183.
  3. 3.Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med. 2019;380(7):651-663.
  4. 4.Lorber B, Swenson RM. Bacteriology of aspiration pneumonia. A prospective study of community- and hospital-acquired cases. Ann Intern Med. 1974;81(3):329-331.
  5. 5.Smith DT. Experimental aspiratory abscess. Arch Surg. 1927;14(1):231-239.
  6. 6.File TM, Fass RJ, Prior RB. Response of mice to transtracheal pulmonary inoculation of anaerobic bacteria. Lab Anim. 1982;16(4):348-350.
  7. 7.Kannangara DW, Thadepalli H, Bach VT, et al. Animal model for anaerobic lung abscess. Infect Immun. 1981;31(2):592-597.
  8. 8.Shinzato T, Saito A. A mechanism of pathogenicity of “Streptococcus milleri group” in pulmonary infection: synergy with an anaerobe. J Med Microbiol. 1994;40(2):118-123.
  9. 9.Eftimiadi C, Tonetti M, Cavallero A, et al. Short-chain fatty acids produced by anaerobic bacteria inhibit phagocytosis by human lung phagocytes. J Infect Dis. 1990;161(1):138-142.
  10. 10.Bartlett JG, Gorbach SL, Finegold SM. The bacteriology of aspiration pneumonia. Am J Med. 1974;56(2):202-207.
  11. 11.Wang JL, Chen KY, Fang CT, et al. Changing bacteriology of adult community-acquired lung abscess in Taiwan: Klebsiella pneumoniae versus anaerobes. Clin Infect Dis. 2005;40(7):915-922.
  12. 12.Takayanagi N, Kagiyama N, Ishiguro T, et al. Etiology and outcome of community-acquired lung abscess. Respiration. 2010;80(2):98-105.
  13. 13.Maitre T, Ok V, Calin R, et al. Pyogenic lung abscess in an infectious disease unit: a 20-year retrospective study. Ther Adv Respir Dis. 2021;15:17534666211003012.
  14. 14.Montméat V, Bonny V, Urbina T, et al. Epidemiology and clinical patterns of lung abscesses in ICU: A French multicenter retrospective study. Chest. 2024;165(1):48-57.
  15. 15.Rolston KVI, Nesher L. Post-obstructive pneumonia in patients with cancer: a review. Infect Dis Ther. 2018;7(1):29-38.
  16. 16.Hsu-Kim C, Hoag JB, Cheng GS, et al. The microbiology of postobstructive pneumonia in lung cancer patients. J Bronchology Interv Pulmonol. 2013;20(3):266-270.
  17. 17.Yazbeck MF, Dahdel M, Kalra A, et al. Lung abscess: update on microbiology and management. Am J Ther. 2014;21(3):217-221.
  18. 18.Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. 2019;200(7):e45-e67.
  19. 19.Boucher B, Virlan D, Buddharaju V, et al. Conservative approach and management of complicated lung abscess. Cureus. 2022;14(11):e31910.
  20. 20.Chiang PC, Lin CY, Hsu YC, et al. Early drainage reduces the length of hospital stay in patients with lung abscess. Front Med (Lausanne). 2023;10:1206419.
  21. 21.Kelogrigoris M, Tsagouli P, Stathopoulos K, et al. CT-guided percutaneous drainage of lung abscesses: review of 40 cases. JBR-BTR. 2011;94(4):191-195.
  22. 22.Lee JH, Hong H, Tamburrini M, et al. Percutaneous transthoracic catheter drainage for lung abscess: a systematic review and meta-analysis. Eur Radiol. 2022;32(2):1184-1194.
  23. 23.Soni NJ, Franco R, Velez MI, et al. Ultrasound in the diagnosis and management of pleural effusions. J Hosp Med. 2015;10(12):811-816.
  24. 24.Wilcox ME, Chong CAKY, Stanbrook MB, et al. Does this patient have an exudative pleural effusion? The Rational Clinical Examination Systematic Review. JAMA. 2014;311(23):2422-2431.
  25. 25.Porcel JM, Esquerda A, Vives M, et al. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014;50(5):161-165.
  26. 26.Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Chest. 1997;111(4):970-980.
  27. 27.Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc. 2006;3(1):75-80.
  28. 28.Li P, An J, Wang S, et al. Incidence and prognostic role of pleural effusion in patients with pulmonary embolism: a systematic review and meta-analysis. J Clin Med. 2023;12(6):2315.
  29. 29.Redden MD, Chin TY, van Driel ML. Surgical versus non-surgical management for pleural empyema. Cochrane Database Syst Rev. 2017(3):CD010651.

Current edition

Hepatitis Overview

Hepatitis Overview

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.